CLINICAL_TRIALS
trial_result
· 2021-02-21
Clinical Trial Update: Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma [Phase 2]
Summary
A Phase 2 clinical trial evaluating hydroxyurea for recurrent and/or unresectable meningioma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UNICANCER | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED